Dendritic cells in cancer immunotherapy

Annual Review of Immunology

Volumn 18, Issue , 2000, Pages 245-273

  Fong, Lawrence ^a   Engleman, Edgar G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; T cell; Tumor immunology; Vaccine

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; LYMPHOMA; MELANOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR IMMUNITY; VACCINATION;

ANIMALS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 0034121654     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.immunol.18.1.245     Document Type: Review

References (130)

1. Hengel H, Lindner M, Wagner H, Heeg K. 1987. Frequency of herpes simplex virus-specific murine cytotoxic T lymphocyte precursors in mitogen-and antigen-driven primary in vitro T cell responses. J. Immunol. 139:4196-4202
2. Kast WM, Boog CJ, Roep BO, Voordouw AC, Melief CJ. 1988. Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells. J. Immunol. 140:3186-93
3. Nonacs R, Humborg C, Tam JP, Steinman RM. 1992. Mechanisms of mouse spleen dendritic cell function in the generation of influenza-specific, cytolytic T lymphocytes. J. Exp. Med. 176:519-29
4. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, ter Schegget J, Melief CJ, Kast WM. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-49
5. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-87
6. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. 1994. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:337-65
7. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97
8. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-22
9. Flamand V, Sornasse T, Thielemans K, Demanet C, Bakkus M, Bazin H, Tielemans F, Leo O, Urbain J, Moser M. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24:605-10
10. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302
11. Hart DN. 1997. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245-87
12. Hart DN, Prickett TC. 1993. Adhesion molecules in tonsil DC-T cell interactions. Adv. Exp. Med. Biol. 329:65-69
13. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, Liu YJ, Rousset F, Saeland S. 1994. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12:881-922
14. Fagnoni FF, Takamizawa M, Godfrey WR, Rivas A, Azuma M, Okumura K, Engleman EG. 1995. Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Immunology 85:467-74
15. Takamizawa M, Rivas A, Fagnoni F, Benike C, Kosek J, Hyakawa H, Engleman EG. 1997. Dendritic cells that process and present nominal antigens to naive T lymphocytes are derived from CD2 + precursors. J. Immunol. 158: 2134-42
16. McLellan AD, Starling GC, Williams LA, Hock BD, Hart DN. 1995. Activation of human peripheral blood dendritic cells induces the CD86 co-stimulatory molecule [published erratum appears in Eur. J. Immunol. 1995 Dec;25(12):3525]. Eur. J. Immunol. 25:2064-68
17. Zhou LJ, Schwarting R, Smith HM, Tedder TF. 1992. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J. Immunol. 149:735-42
18. Hock BD, Starling GC, Daniel PB, Hart DN. 1994. Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allo-stimulatory cells within peripheral blood, including dendritic cells. Immunology 83:573-81
19. Nussenzweig MC, Steinman RM, Witmer MD, Gutchinov B. 1982. A monoclonal antibody specific for mouse dendritic cells. Proc. Natl. Acad. Sci. USA 79:161-65
20. Metlay JP, Witmer-Pack MD, Agger R, Crowley MT, Lawless D, Steinman RM. 1990. The distinct leukocyte integrins of mouse spleen dendritic cells as identified with new hamster monoclonal antibodies. J. Exp. Med. 171:1753-71
21. Kraal G, Breel M, Janse M, Bruin G. 1986. Langerhans' cells, veiled cells, and interdigitating cells in the mouse recognized by a monoclonal antibody. J. Exp. Med. 163:981-97
22. Mehta-Damani A, Markowicz S, Engleman EG. 1995. Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur. J. Immunol. 25:1206-11
23. Mehta-Darnani A, Markowicz S, Engleman EG. 1994. Generation of antigen-specific CD8+ CTLs from naive precursors. J. Immunol. 153:996-1003
24. Steinman RM, Witmer MD. 1978. Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice. Proc. Natl. Acad. Sci. USA 75:5132-36
25. Inaba K, Steinman RM. 1986. Accessory cell-T lymphocyte interactions. Antigen-dependent and -independent clustering. J. Exp. Med. 163:247-61
26. Inaba K, Romani N, Steinman RM. 1989. An antigen-independent contact mechanism as an early step in T cell-proliferative responses to dendritic cells. J. Exp. Med. 170:527-42
27. Reis e Sousa C, Stahl PD, Austyn JM. 1993. Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med. 178:509-19
28. Hart DN, McKenzie JL. 1988. Isolation and characterization of human tonsil dendritic cells. J. Exp. Med. 168:157-70
29. Lanzavecchia A. 1996. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol. 8:348-54
30. Norbury CC, Chambers BJ, Prescott AR, Ljunggren HG, Watts C. 1997. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur. J. Immunol. 27:280-88
31. Arnold-Schild D, Hanau D, Spehner D, Schmid C, Rammensee HG, de la Salle H, Schild H. 1999. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J. Immunol. 162:3757-60
32. Macatonia SE, Taylor PM, Knight SC, Askonas BA. 1989. Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. Exp. Med. 169:1255-64
33. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy. R 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58
34. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-32
35. Palucka KA, Taquet N, Sanchez-Chapuis F, Gluckman JC. 1998. Dendritic cells as the terminal stage of monocyte differentiation. J. Immunol. 160:4587-95
36. Oehler L, Majdic O, Pickl WF, Stockl J, Riedl E, Drach J, Rappersberger K, Geissler K, Knapp W. 1998. Neutrophil granulocyte-committed cells can be driven to acquire dendritic cell characteristics. J. Exp. Med. 187:1019-28
37. Vremec D, Zorbas M, Scollay R, Saunders DJ, Ardavin CF, Wu L, Shortman K. 1992. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J. Exp. Med. 176:47-58
38. Ardavin C, Wu L, Li CL, Shortman K. 1993. Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362:761-63
39. Wu L, Li CL, Shortman K. 1996. Thymic dendritic cell precursors: relationship to the T lymphocyte lineage and phenotype of the dendritic cell progeny. J. Exp. Med. 184:903-11
40. Suss G, Shortman K. 1996. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J. Exp. Med. 183:1789-96
41. DiMolfetto L, Reilly C, Wei Q. Lo D. 1997. Dendritic-like cells from relB mutant mice. Adv. Exp. Med. Biol. 417:47-54
42. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, Olson D, Tizard R, Cate R, Lo D. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373:531-36
43. Wu L, Nichogiannopoulou A, Shortman K, Georgopoulos K. 1997. Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage. Immunity 7:483-92
44. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. 1999. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl. Acad. Sci. USA 96:1036-41
45. Maldonado-Lopez R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, Thielemans K, Leo O, Urbain J, Moser M. 1999. CD8α+ and CD8α-subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J. Exp. Med. 189:587-92
46. Galy A, Travis M, Cen D, Chen B. 1995. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 3:459-73
47. Marquez C, Trigueros C, Franco JM, Ramiro AR, Carrasco YR, Lopez-Botet M, Toribio ML. 1998. Identification of a common developmental pathway for thymic natural killer cells and dendritic cells. Blood 91:2760-71
48. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. 1997. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J. Exp. Med. 185:1101-11
49. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, Lund-Johansen F. 1997. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. USA. 94:12551-56
50. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ. 1999. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283:1183-86
51. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ. 1999. The nature of the principal type 1 interferon-producing cells in human blood. Science 284:1835-37
52. Austyn JM, Larsen CP. 1990. Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation 49:1-7
53. Robert C, Fuhlbrigge RC, Kieffer JD, Ayehunie S, Hynes RO, Cheng G, Grabbe S, von Andrian UH, Kupper TS. 1999. Interaction of dendritic cells with skin endothelium: A new perspective on immunosurveillance. J. Exp. Med. 189:627-36
54. Greaves DR, Wang W, Dairaghi DJ, Dieu MC, Saint-Vis B, Franz-Bacon K, Rossi D, Caux C, McClanahan T, Gordon S, Zlotnik A, Schall TJ. 1997. CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J. Exp. Med. 186:837-44
55. Sozzani S, Allavena P, D'Amico G, Luini W, Bianchi G, Kataura M, Imai T, Yoshie O, Bonecchi R, Mantovani A. 1998. Cutting edge: differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161:1083-86
56. Albert ML, Sauter B, Bhardwaj N. 1998. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392:86-89
57. Svensson M, Stockinger B, Wick MJ. 1997. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J. Immunol. 158:4229-36
58. Pure E, Inaba K, Crowley MT, Tardelli L, Witmer-Pack MD, Ruberti G, Fathman G, Steinman RM. 1990. Antigen processing by epidermal Langerhans cells correlates with the level of biosynthesis of major histocompatibility complex class II molecules and expression of invariant chain. J. Exp. Med. 172:1459-69
59. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373-86
60. Chan VW, Kothakota S, Rohan MC, Panganiban-Lustan L, Gardner JP, Wachowicz MS, Winter JA, Williams LT. 1999. Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood 93:3610-16
61. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S, Foster J, Xu Y, Nooyen P, McClanahan T, Bacon KB, Figdor CG. 1997. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387:713-17
62. Tang HL, Cyster JG. 1999. Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284:819-22
63. Zhou LJ, Tedder TF. 1995. A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. Blood 86:3295-3301
64. Armitage RJ, Namen AE, Sassenfeld HM, Grabstein KH. 1990. Regulation of human T cell proliferation by IL-7. J. lmmunol. 144:938-41
65. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinman RM, Romani N, Schuler G. 1996. Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur. J. Immunol. 26:659-68
66. Yawalkar N, Brand CU, Braathen LR. 1996. IL-12 gene expression in human skin-derived CD1a+ dendritic lymph cells. Arch. Dermatol. Res. 288:79-84
67. Steinman RM. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-96
68. Ridge JP, Di Rosa F, Matzinger P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-78
69. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-80
70. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-83
71. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L. 1999. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5:405-11
72. Steinman RM, Adams JC, Cohn ZA. 1975. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J. Exp. Med. 141:804-20
73. Van Voorhis WC, Hair LS, Steinman RM, Kaplan G. 1982. Human dendritic cells. Enrichment and characterization from peripheral blood. J. Exp. Med. 155:1172-87
74. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702
75. Markowicz S, Engleman EG. 1990. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro. J. Clin. Invest. 85:955-61
76. Caux C, Dezutter-Dambuyant C, Schmitt D, Banchereau J. 1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 360:258-61
77. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83-93
78. Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA. 1995. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1099-1104
79. Sallusto F, Lanzavecchia A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1109-18
80. Rosenzwajg M, Canque B, Gluckman JC. 1996. Human dendritic cell differentiation pathway from CD34+ hematopoietic precursor cells. Blood 87:535-44
81. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ. 1996. Dramatic increase in the numbers of functionally mature dendritic cells in FIt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J. Exp. Med. 184:1953-62
82. Lotze MT, Hellerstedt B, Stolinski L, Tueting T, Wilson C, Kinzler D, Vu H, Rubin JT, Storkus W, Tahara H, Elder E, Whiteside T. 1997. The role of interleukin-2, interleukin-12, and dendritic cells in cancer therapy. Cancer J. Sci. Am. 3:S109
83. Fong L, Benike C, Brockstedt C, Strang G, Hao ZM, Smits B, Ruegg CL, Engleman EG. 1999. Immunization with dendritic cells pulsed with xenogeneic prostatic acid phosphatase administered via different routes induces cellular immune responses in prostate cancer patients. Proc. Am. Assoc. Cancer Res. 40:85
84. Fields RC, Shimizu K, Mule JJ. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:9482-87
85. Gong J, Chen D, Kashiwaba M, Kufe D. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:558-61
86. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. 1996. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170:111-19
87. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357-65
88. Murray RJ, Kurilla MG, Brooks JM, Thomas WA, Rowe M, Kieff E, Rickinson AB. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J. Exp. Med. 176:157-68
89. Kawashima I, Hudson SJ, Tsai V, South-wood S, Takesako K, Appella E, Sette A, Celis E. 1998. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol. 59:1-14
90. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. 1998. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat. Biotechnol. 16:364-69
91. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677-85
92. Feltkamp MC, Vreugdenhil GR, Vierboom MP, Ras E, van der Burg SH, ter Schegget J, Melief CJ, Kast WM. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-42
93. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. lmmunol. 158:1796-1802
94. Maryanski JL, Marchand M, Uyttenhove C, Boon T. 1983. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen-loss secondary variants. Int. J. Cancer. 31:119-23
95. Seung S, Urban JL, Schreiber H. 1993. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J. Exp. Med. 178:933-40
96. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. 1997. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J. Immunol. 159:3113-17
97. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "Self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-86
98. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57:4570-77
99. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. 1998. Immunologie and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-27
100. Alters SE, Gadea JR, Sorich M, O'Donoghue G, Talib S, Philip R. 1998. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. J. Immunother. 21:17-26
101. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP. 1997. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides. Prostate 32:272-78
102. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB. 1997. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159:1666-68
103. Goletz TJ, Klimpel KR, Leppla SH, Keith JM, Berzofsky JA. 1997. Delivery of antigens to the MHC class I pathway using bacterial toxins. Hum. Immunol. 54:129-36
104. Tuting T, Wilson CC, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL Jr, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. 1998. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α. J. Immunol. 160:1139-47
105. Dietz AB, Vuk-Pavlovic S. 1998. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91:392-98
106. Kim CJ, Cormier J, Roden M, Gritz L, Mazzara GP, Fetsch P, Hijazi Y, Lee KH, Rosenberg SA, Marincola FM. 1998. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann. Surg. Oncol. 5: 64-76
107. Reeves ME, Royal RF, Lam JS, Rosenberg SA, Hwu P. 1996. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res. 56:5672-77
108. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. 1997. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. 17:314-17
109. Johnston JC, Gasmi M, Lim LE, Elder JH, Yee JK, Jolly DJ, Campbell KP, Davidson BL, Sauter SL. 1999. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J. Virol. 73:4991-5000
110. Lynch, RG, Rohrer JW, Odermatt B, Gebel HM, Autry JR, Hoover RG. 1979. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol. Rev. 48:45-80
111. Hsu FJ, Kwak L, Campbell M, Liles T, Czerwinski D, Hart S, Syrengelas A, Miller R, Levy R. 1993. Clinical trials of idiotype-specific vaccine in B-cell lymphomas. Ann. NY Acad. Sci. 690:385-87
112. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R. 1985. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191-209
113. Carroll WL, Lowder JN, Streifer R, Warnke R, Levy S, Levy R. 1986. Idio-type variant cell populations in patients with B cell lymphoma. J. Exp. Med. 164:1566-80
114. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327:1209-15
115. Tjoa BA, Simmons SJ, Bowes VA, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. 1998. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36:39-44
116. Reichardt VL, Okada CY, Liso A, Benike CJ, Stockerl-Goldstein KE, Engleman EG, Blume KG, Levy R. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93:2411-19
117. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC. 1997. FIt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3:625-31
118. Chen B, Shi Y, Smith JD, Choi D, Geiger JD, Mule JJ. 1998. The role of tumor necrosis factor alpha in modulating the quantity of peripheral blood-derived, cytokine-driven human dendritic cells and its role in enhancing the quality of dendritic cell function in presenting soluble antigens to CD4+ T cells in vitro. Blood 91:4652-61
119. Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. 1998. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res. 58:2965-68
120. Gabrilovich DI, Cunningham HT, Carbone DP. 1996. IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer. J. Immunother. Emphasis Tumor Immunol. 19:414-18
121. Shimizu K, Fields RC, Giedlin M, Mule JJ. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96:2268-73
122. Gabrilovich DI, Ciernik IF, Carbone DP. 1996. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol. 170:101-10
123. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [published erratum appears in Nat. Med. 1996 Nov;2(11):1267]. Nat. Med. 2:1096-103
124. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159:4772-80
125. Qin Z, Noffz G, Mohaupt M, Blankenstein T. 1997. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol. 159:770-76
126. Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. 1995. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181:811-16
127. Nestle FO, Nickoloff BJ. 1994. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin. Dermatol Clin. 12:271-82
128. Tsujitani S, Kakeji Y, Watanabe A, Kohnoe S, Maehara Y, Sugimachi K. 1990. Infiltration of dendritic cells in relation to tumor invasion and lymph node metastasis in human gastric cancer. Cancer 66:2012-16
129. Salgaller ML, Lodge PA, Tjoa BA, McLean JG, Ragde H, Kenny RJ, Rogers M, Boynton AL, Murphy GP. 1998. Monitoring of prostate-specific membrane antigen-(PSMA) specific immune responses and prostate markers in a phase II clinical trial with patients infused with dendritic cells pulsed with PSMA-derived peptides. Proc. Am. Assoc. Cancer Res. 39:173
130. Valone FH, Small EJ, Whisenant S, Peshwa MV, Strang G, Laus R, van Schooten WCA. 1998. Antigen-pulsed dendritic cell therapy for hormone refractory prostate cancer: A phase I/II trial. Proc. Am. Assoc. Cancer Res. 39:173